Comparison of the effect of rhodium citrate-associated iron oxide nanoparticles on metastatic and non-metastatic breast cancer cells

• Published in: Cancer nanotechnology Vol. 10; no. 1; pp. 1 - 12
• Main Authors: Chaves, Natalia Lemos, Amorim, Danilo Aquino, Lopes, Cláudio Afonso Pinho, Estrela-Lopis, Irina, Böttner, Julia, de Souza, Aparecido Ribeiro, Báo, Sônia Nair
• Format: Journal Article
• Language: English
• Published: Vienna Springer Vienna 11.09.2019; Springer Nature B.V; BMC
• Subjects: Biochemistry; Biomedical Engineering and Bioengineering; Biotechnology; Breast cancer; Cancer Research; Cell cycle; Cell death; Chemistry and Materials Science; Cytotoxicity; Drugs; Exposure; Glycoproteins; Iron oxides; Maghemite; Materials Science; MCF-7; MDA-MB-231; Metastasis; Metastatic cells; Nanocomposites; Nanomaterials; Nanoparticles; Nanotechnology; Nuclei (cytology); Rhodium; Time dependence; Toxicity; Tumors; MCF-7; Maghemite; MDA-MB-231; Metastatic cells
• ISSN: 1868-6958; 1868-6966
• DOI: 10.1186/s12645-019-0052-1

Background Nanocarriers have the potential to improve the therapeutic index of currently available drugs by increasing drug efficacy, lowering drug toxicity and achieving steady-state therapeutic levels of drugs over an extended period. The association of maghemite nanoparticles (NPs) with rhodium citrate (forming the complex hereafter referred to as MRC) has the potential to increase the specificity of the cytotoxic action of the latter compound, since this nanocomposite can be guided or transported to a target by the use of an external magnetic field. However, the behavior of these nanoparticles for an extended time of exposure to breast cancer cells has not yet been explored, and nor has MRC cytotoxicity comparison in different cell lines been performed until now. In this work, the effects of MRC NPs on these cells were analyzed for up to 72 h of exposure, and we focused on comparing NPs’ therapeutic effectiveness in different cell lines to elect the most responsive model, while elucidating the underlying action mechanism. Results MRC complexes exhibited broad cytotoxicity on human tumor cells, mainly in the first 24 h. However, while MRC induced cytotoxicity in MDA-MB-231 in a time-dependent manner, progressively decreasing the required dose for significant reduction in cell viability at 48 and 72 h, MCF-7 appears to recover its viability after 48 h of exposure. The recovery of MCF-7 is possibly explained by a resistance mechanism mediated by PGP (P-glycoprotein) proteins, which increase in these cells after MRC treatment. Remaining viable tumor metastatic cells had the migration capacity reduced after treatment with MRC (24 h). Moreover, MRC treatment induced S phase arrest of the cell cycle. Conclusion MRC act at the nucleus, inhibiting DNA synthesis and proliferation and inducing cell death. These effects were verified in both tumor lines, but MDA-MB-231 cells seem to be more responsive to the effects of NPs. In addition, NPs may also disrupt the metastatic activity of remaining cells, by reducing their migratory capacity. Our results suggest that MRC nanoparticles are a promising nanomaterial that can provide a convenient route for tumor targeting and treatment, mainly in metastatic cells.